<DOC>
	<DOCNO>NCT01082523</DOCNO>
	<brief_summary>The purpose study determine whether automate electronic reminder system use text message send patient 's cell phone help patient acne compliant topical medication lead improvement acne . Hypothesis : Automatically deliver electronic reminder form text message increase acne patient adherence topical medication consequently result well treatment outcome high patient satisfaction</brief_summary>
	<brief_title>`` A Randomized , Controlled , Evaluator-blinded Pilot Study Evaluate Effect Automated Text Message Reminders Patient Compliance With Topical Medications Its Efficacy Skin Disease Control Adolescents Adults With Mild Moderate Acne ''</brief_title>
	<detailed_description>Patient non-compliance topical medication use significant determinant treatment failure result patient physician frustration outcome lead suboptimal medical care . It important address way improve patient compliance medical economic standpoint , adequate use medication could lead reduction unnecessary office visit cost-effective use prescribed medication . Patients mild moderate acne prescribed standard treatment regimen clindamycin/benzoyl peroxide gel morning adapalene gel evening . Half subject randomly assign receive customize text message instruct twice day apply morning even cream prescribed , remainder subject serve control . Each medication tube supply every subject fit electronic Medication Event Monitoring System cap ( MEMS cap ) ability record date time every opening/closing tube . This data serve objective measure medication use use determine whether reminder message result higher consistent use prescribed medication . Specific Aims : The primary aim study determine whether automate text message produce increase adherence medication use Reminder group compare Control group 12 week study duration . Improvement acne measure use full face lesion count , Investigator Global Assessment Score ( IGA ) subject Global Assessment Score ( SGA ) . Quality life satisfaction measure use Dermatology Life Quality Index ( DLQI ) , patient satisfaction survey .</detailed_description>
	<mesh_term>Skin Diseases</mesh_term>
	<criteria>male female 1230 year age time consent ethnic background capable give informed consent clinical diagnosis acne vulgaris facial involvement least 6 month prior enrollment . Must minimum 30 100 noninflammatory facial lesion ( open and/or close comedo ) , 20 50 inflammatory lesion ( papule pustule ) nodule cyst . Must score 2 3 Investigator Global Assessment Scale ( IGA ) Must personal mobile telephone SMS text messaging capability . Must English Spanish speaking . Women child bear potential men must use adequate birth control measure ( e.g . abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) must agree continue use measure become pregnant plan pregnancy 12 month receive last dose study medication . Must able adhere study visit schedule protocol requirement . Must avoid prolonged sun exposure avoid use tan booths ultraviolet light source study . Must agree use prescription counter medication one prescribe study protocol . Must agree limit Vitamin A supplementation total daily dose 40005000 IU . Nodular cystic acne , acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced , mechanical ) Known exposure history environmental chemical comedogenic agent cut oil , tar , halogenated compound polyaromatic hydrocarbon . Women know history clinical evidence hyperandrogenism polycystic ovarian syndrome . Known history clinical evidence Cushing 's syndrome congenital adrenal hyperplasia . Use hormonal contraceptive intrauterine device ( unless subject stable dose , i.e least 6 month prior treatment Have use investigational drug within previous 4 week 5 time half life investigational drug , whichever longer . Have receive phototherapy use tan booth within 4 week prior enrollment Currently take systemic medication could affect evaluation acne ( include , limited antibiotic , retinoids , biologic disease modify agent , chemotherapeutic agent , antiepileptic agent EGFRreceptor antagonist ) History chronic recurrent infectious disease , include , limited folliculitis , infect skin wound ulcer recurrent herpes simplex infection . Known hypersensitivity response , include anaphylaxis , compound use treatment ( e.g : clindamycin , retinoids ) . Known substance abuse ( drug alcohol ) problem within previous 12 month . Presence beard facial hair might interfere study assessment Participating another clinical trial use investigational agent procedure participation study . Are pregnant plan pregnancy surgery participation study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>